# Cellyan Biotechnology Co., Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cellyan Biotechnology Co., Ltd). ## Overview Cellyan Biotechnology Co., Ltd is a Cayman Islands holding company with operating subsidiaries in Hong Kong that serve the OTC pharmaceutical cross-border trade market. Its business centers on supply chain services and direct procurement/distribution of over-the-counter pharmaceutical products for customers accessing overseas goods through Chinese e-commerce channels. ## Products & services • OTC pharmaceutical cross-border e-commerce supply chain services • OTC pharmaceutical cross-border procurement and distribution • Pre-consultation and product information review • Import/export permits, enlistment, storage, packaging, logistics • Direct sales to merchants and pharmaceutical distributors - **Cross-border OTC pharmaceutical supply chain** (55%) — End-to-end services that help Mainland Chinese customers access OTC drugs from outside Mainland China. - **Cross-border procurement and distribution** (45%) — Procurement, wholesaling, and distribution of overseas OTC pharmaceutical products through Hong Kong entities. - OTC pharmaceutical cross-border e-commerce supply chain services - OTC pharmaceutical cross-border procurement and distribution - Pre-consultation and product information review - Import/export permits, enlistment, storage, packaging, logistics - Direct sales to merchants and pharmaceutical distributors ## Customers The company serves Mainland Chinese consumers who want access to OTC pharmaceutical products purchased outside Mainland China, typically through e-commerce channels. It also sells to merchants operating on Chinese e-commerce platforms and to pharmaceutical distributors that source overseas OTC products for onward sale. Its service model depends on suppliers, logistics providers, and platform merchants working together to move regulated health products across borders. - **Mainland Chinese consumers** (primary) — Buy OTC pharmaceutical products sourced outside Mainland China through cross-border channels and logistics support. - **E-commerce merchants** (primary) — Purchase OTC products and supply-chain services to resell through established Chinese online platforms. - **Pharmaceutical distributors** (secondary) — Source overseas OTC products for wholesale distribution and market access. - **Supplier and logistics ecosystem** (secondary) — Works with the company to enable procurement, storage, packaging, and delivery execution. - Mainland Chinese consumers seeking overseas OTC medicines - Chinese e-commerce platform merchants - Pharmaceutical distributors - OTC pharmaceutical suppliers and logistics partners - Customers needing end-to-end import and delivery support ## Geography Cellyan is incorporated in the Cayman Islands but its operating footprint is centered in Hong Kong through its subsidiaries, with commercial activity tied to Mainland China demand. The company also uses Hong Kong as the operational hub for regulatory handling, warehousing, and cross-border logistics, while its customers and e-commerce channels are largely China-facing. This structure makes the business dependent on Hong Kong operating conditions and on cross-border trade rules affecting the PRC market. - Cayman Islands parent company with Hong Kong subsidiaries - Hong Kong is the operating and logistics hub - Mainland China is the core demand market - Cross-border flows depend on Hong Kong and PRC rules - Shenzhen is used for shareholder meeting operations ## Strategy The company’s strategy is to maintain a competitive value proposition in OTC cross-border pharmaceutical trade by combining procurement, regulatory handling, warehousing, and delivery into one service chain. It also emphasizes retaining key customers, improving marketing and sales execution, and adapting its supply chain to remain competitive as sourcing and transport conditions change. - **Strengthen integrated cross-border service offering** (short-term) — A bundled procurement-to-delivery model differentiates the company in OTC pharmaceutical trade. - **Retain and expand key customer relationships** (short-term) — The business depends on a small number of channel partners and merchants to drive demand. - **Improve supply chain flexibility** (medium-term) — Sourcing and transportation costs can change quickly in cross-border pharmaceutical trade. - Maintain a one-stop OTC pharmaceutical value proposition - Retain key customers and trading relationships - Grow through marketing and sales execution - Adapt the supply chain to sourcing and transport changes - Secure financing resources at favorable cost ## Risks The business is exposed to customer concentration, execution risk in cross-border logistics, and changes in import/export or pharmaceutical regulations. Because operations rely on Hong Kong subsidiaries and Mainland China-facing demand, PRC policy changes, FX controls, or trade restrictions could affect cash movement and operating continuity. Competition, supply chain disruption, and dependence on a key customer also create meaningful volatility in a relatively narrow operating model. - **Key customer concentration** [high] — The company states that maintaining its key customer is a principal factor affecting performance. - **Cross-border regulatory change** [high] — OTC pharmaceutical trade depends on permits, HKDOH enlistment, and import/export compliance. - **PRC/Hong Kong cash transfer restrictions** [high] — The holding company relies on dividends from Hong Kong subsidiaries for cash requirements. - **Supply chain cost volatility** [medium] — Changes in product purchasing and transportation costs can affect competitiveness. - **Geopolitical and economic sensitivity** [medium] — Demand and costs can be affected by broader economic and political conditions in global markets. - Dependence on a key customer and limited diversification - Regulatory risk around OTC imports and cross-border compliance - Supply chain disruption can raise procurement and transport costs - PRC/Hong Kong policy changes could limit cash transfers - Competition may pressure the value proposition and merchant retention ## Accounting The company’s reporting likely depends on judgment in revenue recognition across service and product-sale arrangements, especially where procurement, logistics, and delivery are bundled together. It also highlights impairment losses as a key estimate area, while its holding-company structure and reliance on subsidiary dividends make cash flow and distribution-related disclosures important for analysis. - **Revenue recognition** — Affects reported revenue timing and comparability across periods - **Impairment losses** — May reduce carrying values of assets or other balances - **Dividend restrictions and subsidiary transfers** — Affects liquidity at the holding-company level - **Estimates and assumptions** — Can influence provisions, accruals, and asset valuations - Revenue recognition for bundled cross-border service arrangements - Timing of product sales versus logistics/service completion - Impairment assessment for assets and other long-lived balances - Dividend reliance from Hong Kong subsidiaries at the holding company - Judgment around estimates and assumptions in financial reporting --- *Last updated: 2026-09-28T11:58:11.166191+00:00*